Quarterly ResultMay 8, 2026, 07:03 AM
Boundless Bio KOMODO-1 Enrollment Ongoing; $92.8M Cash Funds to H2 2028
AI Summary
Boundless Bio announced its Q1 2026 financial results and provided business highlights, including ongoing enrollment in the KOMODO-1 clinical trial for BBI-940. The company reported a cash position of $92.8 million as of March 31, 2026, which is expected to fund operations into the second half of 2028, covering the anticipated initial clinical proof-of-concept readout for KOMODO-1. Net loss for the quarter improved to $13.6 million from $15.8 million in the prior year, with reduced R&D and G&A expenses. Preclinical data supporting BBI-940's mechanism and anti-tumor activity were also presented at the 2026 AACR Annual Meeting.
Key Highlights
- Enrollment is ongoing in the KOMODO-1 first-in-human clinical trial for BBI-940.
- Initial safety and efficacy clinical proof-of-concept data for KOMODO-1 are expected within the existing cash runway.
- Cash, cash equivalents, and short-term investments totaled $92.8 million as of March 31, 2026.
- The company expects its cash to fund operations into the second half of 2028.
- Net loss for Q1 2026 was $13.6 million, compared to $15.8 million for Q1 2025.
- Research and Development expenses decreased to $9.7 million in Q1 2026 from $12.1 million in Q1 2025.
- General and Administrative expenses decreased to $4.7 million in Q1 2026 from $5.2 million in Q1 2025.
- Preclinical data presented at AACR 2026 demonstrated BBI-940's anti-tumor activity and tumor regression.